Wefunder logo

Sanatela Life Sciences Inc. (SLS)

COVID-19 Pneumonia patients may soon need Mesenchymal Stem Cells (MSC) from SLS

Follow Sanatela Life Sciences Inc. (SLS) to be notified if they later decide to raise funding.

Highlights

1
April 5, 2020 the US FDA approved (MSC) treatments for use in the very sickest COVID-19 patients know as expanded access compassionate use
2
Clinical studies show MSC injections significantly improved pulmonary function & symptoms of COVID-19 patients without any adverse effects
3
Fast-tracked emergency FDA approval submitted for use of MSCs to treat COVID-19 pneumonia patients, especially those in critical condition
4
One of the world's leading stem cell R&D firms asked Sanatela (SLS) to pivot to produce enough MSCs to get patients off ventilators faster

Our Team

To create our Sanatela Matrix 3D bioengineered tissue products, we first decellularize WJ found within umbilical cords. We have always intended to culture & sell the stem cells recovered for research purposes. We want to pivot to MSC injections to save lives by quick ramp-up MSC production repurposed for COVID-19 pneumonia injection treatments.

Sanatela Can Save Millions of Lives Now!

Our parent company, the AT Venture Center advanced technology accelerator, has spawned a family of biotech start-ups, including Sanatela Life Sciences. These companies are all based on technology that we’ve licensed that uses a material derived from human umbilical cords called Wharton's Jelly to achieve a range of unique medical objectives.

Wharton’s Jelly is a great source of pluripotent stem cells called MSC that proliferate rapidly and do not provoke an immune response. Early on we began working with our scientific advisor Andre Ragnaugh. Dr Andre sits on the advisor board of Blue Horizon Internation with Dr. Dongcheng Wu who is  Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar. Dr. Wu and team conducted a successful clinical trial using stem cells intravenously on severe Covid -19 patients.  Dr. Andre suggested Sanatela pivot our resources and scale up US stem cell manufacturing.

The outbreak of COVID-19 has caused us to urgently shift our focus to concentrate on this line of business. Andre, Dr. Wu, Blue Horizons and scientists around the world are working on very promising research that can potentially use our stem cells to lessen the effects of severe pneumonia in COVID-19 patients and save countless lives.

But they need more MSC stem cells to complete clinical trials and get fast-tracked FDA approval, preferably stem cells that are produced close by, in the US.

In March, 2020 Sanatela leased the perfect lab setting which provides the company room to grow. Our 20,000 sq. ft. of pristine lab space and ancillary office and production space will jump start our stem cell production, and can be expanded to about 50,000 sq. ft. of wet lab and related contiguous space.

The world has changed immeasurably by COVID-19 & we are uniquely positioned to have this opportunity to provide hope to patients desperately in need of treatments & cures.

Downloads

Overview